ID   ACOX2_HUMAN             Reviewed;         681 AA.
AC   Q99424; A6NF16; B2R8U5;
DT   02-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   28-JUN-2023, entry version 194.
DE   RecName: Full=Peroxisomal acyl-coenzyme A oxidase 2 {ECO:0000303|PubMed:14702039};
DE            EC=1.17.99.3 {ECO:0000269|PubMed:27884763};
DE   AltName: Full=3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanoyl-CoA 24-hydroxylase;
DE   AltName: Full=3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanoyl-CoA oxidase {ECO:0000250|UniProtKB:O02767};
DE   AltName: Full=Trihydroxycoprostanoyl-CoA oxidase {ECO:0000250|UniProtKB:P97562};
DE            Short=THCA-CoA oxidase {ECO:0000250|UniProtKB:O02767};
DE            Short=THCCox;
GN   Name=ACOX2 {ECO:0000312|HGNC:HGNC:120};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 8-14; 271-282; 337-346;
RP   450-468 AND 656-664, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=8943006; DOI=10.1073/pnas.93.24.13748;
RA   Baumgart E., Vanhooren J.C.T., Fransen M., Marynen P., Puype M.,
RA   Vandekerckhove J., Leunissen J.A.M., Fahimi H.D., Mannaerts G.P.,
RA   Van Veldhoven P.P.;
RT   "Molecular characterization of the human peroxisomal branched-chain acyl-
RT   CoA oxidase: cDNA cloning, chromosomal assignment, tissue distribution, and
RT   evidence for the absence of the protein in Zellweger's syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:13748-13753(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Fournier B., Baumgart E., Fahimi D., Mannaerts G.P., Van Veldhoven P.P.;
RT   "Genomic sequence of peroxisomal human branched chain acyl-CoA oxidase.";
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9 AND THR-13, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [8]
RP   INVOLVEMENT IN CBAS6, VARIANT CBAS6 69-TYR--LEU-682 DEL, AND
RP   CHARACTERIZATION OF VARIANT CBAS6 69-TYR--LEU-682 DEL.
RX   PubMed=27647924; DOI=10.1073/pnas.1613228113;
RA   Vilarinho S., Sari S., Mazzacuva F., Bilguevar K., Esendagli-Yilmaz G.,
RA   Jain D., Akyol G., Dalgic B., Guenel M., Clayton P.T., Lifton R.P.;
RT   "ACOX2 deficiency: A disorder of bile acid synthesis with transaminase
RT   elevation, liver fibrosis, ataxia, and cognitive impairment.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:11289-11293(2016).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, INVOLVEMENT IN CBAS6,
RP   VARIANT CBAS6 TRP-225, AND CHARACTERIZATION OF VARIANT CBAS6 TRP-225.
RX   PubMed=27884763; DOI=10.1016/j.jhep.2016.11.005;
RA   Monte M.J., Alonso-Pena M., Briz O., Herraez E., Berasain C., Argemi J.,
RA   Prieto J., Marin J.J.;
RT   "ACOX2 deficiency: An inborn error of bile acid synthesis identified in an
RT   adolescent with persistent hypertransaminasemia.";
RL   J. Hepatol. 66:581-588(2017).
CC   -!- FUNCTION: Oxidizes the CoA esters of the bile acid intermediates
CC       di- and tri-hydroxycholestanoic acids (PubMed:27884763). Capable of
CC       oxidizing short as well as long chain 2-methyl branched fatty acids (By
CC       similarity). {ECO:0000250|UniProtKB:P07872,
CC       ECO:0000269|PubMed:27884763}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(25R)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl-
CC         CoA + A + H2O = (24R,25R)-3alpha,7alpha,12alpha,24-tetrahydroxy-
CC         5beta-cholestan-26-oyl-CoA + AH2; Xref=Rhea:RHEA:15733,
CC         ChEBI:CHEBI:13193, ChEBI:CHEBI:15377, ChEBI:CHEBI:17499,
CC         ChEBI:CHEBI:58677, ChEBI:CHEBI:59807; EC=1.17.99.3;
CC         Evidence={ECO:0000269|PubMed:27884763};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:15734;
CC         Evidence={ECO:0000305|PubMed:27884763};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(25S)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl-
CC         CoA + O2 = (24E)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-
CC         en-26-oyl-CoA + H2O2; Xref=Rhea:RHEA:46728, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16240, ChEBI:CHEBI:59879, ChEBI:CHEBI:77251;
CC         Evidence={ECO:0000250|UniProtKB:O02767};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46729;
CC         Evidence={ECO:0000250|UniProtKB:O02767};
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000250|UniProtKB:P07872};
CC   -!- SUBUNIT: Homodimer. {ECO:0000250|UniProtKB:P07872}.
CC   -!- INTERACTION:
CC       Q99424; P63172: DYNLT1; NbExp=3; IntAct=EBI-12026476, EBI-1176455;
CC   -!- SUBCELLULAR LOCATION: Peroxisome {ECO:0000269|PubMed:27884763,
CC       ECO:0000269|PubMed:8943006}.
CC   -!- TISSUE SPECIFICITY: Present in all tissues tested: heart, brain,
CC       placenta, lung, liver, skeletal muscle, kidney and pancreas. Most
CC       abundant in heart, liver and kidney. {ECO:0000269|PubMed:8943006}.
CC   -!- DISEASE: Congenital bile acid synthesis defect 6 (CBAS6) [MIM:617308]:
CC       An inborn error of bile acid synthesis characterized by abnormally
CC       increased liver enzymes, hypolipidemia and low cholesterol, vitamin D
CC       deficiency, elevated plasma and urinary levels of C27 intermediate bile
CC       acids 3alpha,7alpha-dihydroxy-5beta-cholestanoic acid (DHCA) and
CC       3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoic acid (THCA). Serum
CC       levels of phytanic and pristanic acids are normal. Clinical features
CC       include liver fibrosis, mild ataxia, delayed development, and cognitive
CC       impairment. Liver histology shows many thin fibrous septa, swollen
CC       hepatocytes, glycogenated nuclei, and focal acinar transformation,
CC       consistent with hepatocellular injury and regeneration, without signs
CC       of obvious cholestasis, cholate stasis, or steatosis. CBAS6
CC       transmission pattern is consistent with autosomal recessive
CC       inheritance. {ECO:0000269|PubMed:27647924,
CC       ECO:0000269|PubMed:27884763}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the acyl-CoA oxidase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X95190; CAA64489.1; -; mRNA.
DR   EMBL; AJ001541; CAB65596.1; -; Genomic_DNA.
DR   EMBL; AJ001542; CAB65596.1; JOINED; Genomic_DNA.
DR   EMBL; AJ001543; CAB65596.1; JOINED; Genomic_DNA.
DR   EMBL; AJ001544; CAB65596.1; JOINED; Genomic_DNA.
DR   EMBL; AJ001545; CAB65596.1; JOINED; Genomic_DNA.
DR   EMBL; AJ001546; CAB65596.1; JOINED; Genomic_DNA.
DR   EMBL; AJ001547; CAB65596.1; JOINED; Genomic_DNA.
DR   EMBL; AJ001548; CAB65596.1; JOINED; Genomic_DNA.
DR   EMBL; AK313512; BAG36292.1; -; mRNA.
DR   EMBL; AC116036; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471055; EAW65375.1; -; Genomic_DNA.
DR   EMBL; BC047700; AAH47700.1; -; mRNA.
DR   CCDS; CCDS33775.1; -.
DR   RefSeq; NP_003491.1; NM_003500.3.
DR   RefSeq; XP_005265562.1; XM_005265505.1.
DR   AlphaFoldDB; Q99424; -.
DR   SMR; Q99424; -.
DR   BioGRID; 113906; 6.
DR   IntAct; Q99424; 3.
DR   STRING; 9606.ENSP00000307697; -.
DR   GlyGen; Q99424; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q99424; -.
DR   PhosphoSitePlus; Q99424; -.
DR   SwissPalm; Q99424; -.
DR   BioMuta; ACOX2; -.
DR   DMDM; 17366636; -.
DR   jPOST; Q99424; -.
DR   MassIVE; Q99424; -.
DR   MaxQB; Q99424; -.
DR   PaxDb; Q99424; -.
DR   PeptideAtlas; Q99424; -.
DR   ProteomicsDB; 78260; -.
DR   Antibodypedia; 31666; 334 antibodies from 33 providers.
DR   DNASU; 8309; -.
DR   Ensembl; ENST00000302819.10; ENSP00000307697.5; ENSG00000168306.13.
DR   GeneID; 8309; -.
DR   KEGG; hsa:8309; -.
DR   MANE-Select; ENST00000302819.10; ENSP00000307697.5; NM_003500.4; NP_003491.1.
DR   UCSC; uc003dkl.4; human.
DR   AGR; HGNC:120; -.
DR   CTD; 8309; -.
DR   DisGeNET; 8309; -.
DR   GeneCards; ACOX2; -.
DR   HGNC; HGNC:120; ACOX2.
DR   HPA; ENSG00000168306; Tissue enriched (liver).
DR   MalaCards; ACOX2; -.
DR   MIM; 601641; gene.
DR   MIM; 617308; phenotype.
DR   neXtProt; NX_Q99424; -.
DR   OpenTargets; ENSG00000168306; -.
DR   PharmGKB; PA24444; -.
DR   VEuPathDB; HostDB:ENSG00000168306; -.
DR   eggNOG; KOG0136; Eukaryota.
DR   GeneTree; ENSGT00940000160985; -.
DR   HOGENOM; CLU_014629_3_1_1; -.
DR   InParanoid; Q99424; -.
DR   OMA; CYYISVK; -.
DR   OrthoDB; 5777at2759; -.
DR   PhylomeDB; Q99424; -.
DR   TreeFam; TF300672; -.
DR   BioCyc; MetaCyc:HS09732-MON; -.
DR   PathwayCommons; Q99424; -.
DR   Reactome; R-HSA-193368; Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol.
DR   Reactome; R-HSA-389887; Beta-oxidation of pristanoyl-CoA.
DR   Reactome; R-HSA-9033241; Peroxisomal protein import.
DR   SignaLink; Q99424; -.
DR   BioGRID-ORCS; 8309; 7 hits in 1147 CRISPR screens.
DR   ChiTaRS; ACOX2; human.
DR   GenomeRNAi; 8309; -.
DR   Pharos; Q99424; Tbio.
DR   PRO; PR:Q99424; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q99424; protein.
DR   Bgee; ENSG00000168306; Expressed in right lobe of liver and 134 other tissues.
DR   ExpressionAtlas; Q99424; baseline and differential.
DR   Genevisible; Q99424; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005782; C:peroxisomal matrix; TAS:Reactome.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0033791; F:3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoyl-CoA 24-hydroxylase activity; IDA:UniProtKB.
DR   GO; GO:0071949; F:FAD binding; IEA:InterPro.
DR   GO; GO:0005504; F:fatty acid binding; IBA:GO_Central.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; ISS:UniProtKB.
DR   GO; GO:0016401; F:palmitoyl-CoA oxidase activity; IBA:GO_Central.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0006699; P:bile acid biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0033540; P:fatty acid beta-oxidation using acyl-CoA oxidase; IDA:UniProtKB.
DR   GO; GO:0055088; P:lipid homeostasis; IBA:GO_Central.
DR   GO; GO:0000038; P:very long-chain fatty acid metabolic process; IBA:GO_Central.
DR   Gene3D; 1.10.540.10; Acyl-CoA dehydrogenase/oxidase, N-terminal domain; 1.
DR   Gene3D; 2.40.110.10; Butyryl-CoA Dehydrogenase, subunit A, domain 2; 1.
DR   Gene3D; 1.20.140.10; Butyryl-CoA Dehydrogenase, subunit A, domain 3; 2.
DR   InterPro; IPR029320; Acyl-CoA_ox_N.
DR   InterPro; IPR046373; Acyl-CoA_Oxase/DH_mid-dom_sf.
DR   InterPro; IPR012258; Acyl-CoA_oxidase.
DR   InterPro; IPR002655; Acyl-CoA_oxidase_C.
DR   InterPro; IPR036250; AcylCo_DH-like_C.
DR   InterPro; IPR037069; AcylCoA_DH/ox_N_sf.
DR   InterPro; IPR009100; AcylCoA_DH/oxidase_NM_dom.
DR   PANTHER; PTHR10909; ELECTRON TRANSPORT OXIDOREDUCTASE; 1.
DR   PANTHER; PTHR10909:SF344; PEROXISOMAL ACYL-COENZYME A OXIDASE 2; 1.
DR   Pfam; PF01756; ACOX; 1.
DR   Pfam; PF14749; Acyl-CoA_ox_N; 1.
DR   PIRSF; PIRSF000168; Acyl-CoA_oxidase; 1.
DR   SUPFAM; SSF47203; Acyl-CoA dehydrogenase C-terminal domain-like; 2.
DR   SUPFAM; SSF56645; Acyl-CoA dehydrogenase NM domain-like; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Disease variant; FAD; Fatty acid metabolism;
KW   Flavoprotein; Lipid metabolism; Oxidoreductase; Peroxisome; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN           1..681
FT                   /note="Peroxisomal acyl-coenzyme A oxidase 2"
FT                   /id="PRO_0000204681"
FT   MOTIF           679..681
FT                   /note="Microbody targeting signal"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         3
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97562"
FT   MOD_RES         9
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         13
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         66
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QXD1"
FT   MOD_RES         137
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QXD1"
FT   MOD_RES         453
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QXD1"
FT   MOD_RES         561
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QXD1"
FT   VARIANT         69..681
FT                   /note="Missing (in CBAS6; patient liver samples show
FT                   absence of the protein; complete loss of fatty acid
FT                   beta-oxidation activity)"
FT                   /evidence="ECO:0000269|PubMed:27647924"
FT                   /id="VAR_078764"
FT   VARIANT         225
FT                   /note="R -> W (in CBAS6; reduces fatty acid beta-oxidation
FT                   activity; does not alter subcellular location;
FT                   dbSNP:rs150832314)"
FT                   /evidence="ECO:0000269|PubMed:27884763"
FT                   /id="VAR_078765"
SQ   SEQUENCE   681 AA;  76827 MW;  7FAE9236FCBE6D4D CRC64;
     MGSPVHRVSL GDTWSRQMHP DIESERYMQS FDVERLTNIL DGGAQNTALR RKVESIIHSY
     PEFSCKDNYF MTQNERYKAA MRRAFHIRLI ARRLGWLEDG RELGYAYRAL SGDVALNIHR
     VFVRALRSLG SEEQIAKWDP LCKNIQIIAT YAQTELGHGT YLQGLETEAT YDAATQEFVI
     HSPTLTATKW WPGDLGRSAT HALVQAQLIC SGARRGMHAF IVPIRSLQDH TPLPGIIIGD
     IGPKMDFDQT DNGFLQLNHV RVPRENMLSR FAQVLPDGTY VKLGTAQSNY LPMVVVRVEL
     LSGEILPILQ KACVIAMRYS VIRRQSRLRP SDPEAKVLDY QTQQQKLFPQ LAISYAFHFL
     AVSLLEFFQH SYTAILNQDF SFLPELHALS TGMKAMMSEF CTQGAEMCRR ACGGHGYSKL
     SGLPSLVTKL SASCTYEGEN TVLYLQVARF LVKSYLQTQM SPGSTPQRSL SPSVAYLTAP
     DLARCPAQRA ADFLCPELYT TAWAHVAVRL IKDSVQHLQT LTQSGADQHE AWNQTTVIHL
     QAAKVHCYYV TVKGFTEALE KLENEPAIQQ VLKRLCDLHA IHGILTNSGD FLHDAFLSGA
     QVDMARTAYL DLLRLIRKDA ILLTDAFDFT DQCLNSALGC YDGNVYERLF QWAQKSPTNT
     QENPAYEEYI RPLLQSWRSK L
//
